Facile production of minor metabolites for drug development using a CYP3A shuffled library

Metabolic Engineering

Volumn 13, Issue 6, 2011, Pages 682-693

  Hunter, D J B ^a   Behrendorff, J B Y H ^a   Johnston, W A ^a   Hayes, P Y ^a   Huang, W ^a   Bonn, B ^b   Hayes, M A ^b   De Voss, J J ^a   Gillam, E M J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Cytochrome P450; Drug development; Drug metabolites; Escherichia coli; Laboratory scale bioreactors

Indexed keywords

2D-NMR SPECTROSCOPY; AB INITIO; BATCH CULTURE; CYTOCHROME P450; DIRECTED EVOLUTION; DNA SHUFFLING; DRUG DEVELOPMENT; DRUG METABOLITES; EXPRESSION IN ESCHERICHIA COLI; FACILE ISOLATION; FACILE PRODUCTION; LABORATORY SCALE; MEDICINAL CHEMISTRY; METABOLIC PROFILING; STRUCTURAL DETERMINATION; STRUCTURAL IDENTIFICATION; TRACE AMOUNTS;

BATCH CELL CULTURE; BIOMOLECULES; ESCHERICHIA COLI; METABOLITES; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SUBSTRATES;

METABOLISM;

1BETA HYDROXYTESTOSTERONE; CYTOCHROME P450 3A; DRUG METABOLITE; MIDAZOLAM; MUTANT PROTEIN; PROGESTERONE; TESTOSTERONE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BACTERIUM CULTURE; BIOCATALYST; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; DIRECTED MOLECULAR EVOLUTION; DNA RECOMBINATION; DNA SHUFFLING; DRUG HYDROXYLATION; ENZYME SUBSTRATE; ESCHERICHIA COLI; GENE EXPRESSION; GENE LIBRARY; GENE MUTATION; GENE SEQUENCE; PRIORITY JOURNAL; PROGESTERONE METABOLISM; PROTON NUCLEAR MAGNETIC RESONANCE; SCREENING; SEQUENCE HOMOLOGY; STEROID METABOLISM; TESTOSTERONE METABOLISM;

CYTOCHROME P-450 CYP3A; DNA SHUFFLING; DRUG DISCOVERY; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; GENE LIBRARY; HYDROXYTESTOSTERONES; SUBSTRATE SPECIFICITY; TESTOSTERONE;

ESCHERICHIA COLI;

EID: 80555150588     PISSN: 10967176     EISSN: 10967184     Source Type: Journal    
DOI: 10.1016/j.ymben.2011.09.001     Document Type: Article

References (57)

1. Abécassis V., Pompon D., Truan G. High efficiency family shuffling based on multi-step PCR and in vivo DNA recombination in yeast: statistical and functional analysis of a combinatorial library between human cytochrome P450 1A1 and 1A2. Nucl. Acids Res. 2000, 28:e88.
2. Bloom J.D., Labthavikul S.T., Otey C.R., Arnold F.H. Protein stability promotes evolvability. Proc. Natl. Acad. Sci. USA 2006, 103:5869-5874.
3. Chang T.K.H., Waxman D.J. Enzymatic analysis of cDNA expressed human CYP1A1, CYP1A2 and CYP1B1 with 7-ethoxyresorufin. Methods Mol. Biol. 1998, 103-109. Humana Press, Totowa, NJ. I.R. Phillips, E.A. Shephard (Eds.).
4. Chen L., Buters J.T.M., Hardwick J.P., Tamura S., Penman B.W., Gonzalez F.J., Crespi C.L. Coexpression of cytochrome P4502A6 and human NADPH-P450 oxidoreductase in the baculovirus system. Drug Metab. Dispos. 1997, 25:399-405.
5. Cirino P.C., Mayer K.M., Umeno D. Generating mutant libraries using error-prone PCR. Directed Evolution Library Creation: Methods and Protocols 2003, 3-9. Humana Press, Totowa, NJ. F.H. Arnold, G. Georgiou (Eds.).
6. Damsten M.C., van Vugt-Lussenburg B.M.A., Zeldenthuis T., de Vlieger J.S.B., Commandeur J.N.M., Vermeulen N.P.E. Application of drug metabolising mutants of cytochrome P450BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites. Chem.-Biol. Interact. 2008, 171:96-107.
7. Domanski T.L., He Y.A., Harlow G.R., Halpert J.R. Dual role of human cytochrome P450 3A4 residue phe-304 in substrate specificity and cooperativity. J. Pharmacol. Exp. Ther. 2000, 293:585-591.
8. Ekroos M., Sjögren T. Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. USA 2006, 103:13682-13687.
9. Espina R., Yu L.N., Wang J.Y., Tong Z., Vashishtha S., Talaat R., Scatina J., Mutlib A. Nuclear magnetic resonance spectroscopy as a quantitative tool to determine the concentrations of biologically produced metabolites: implications in metabolites in safety testing. Chem. Res. Toxicol. 2009, 22:299-310.
10. Fischer C.R., Klein-Marcuschamer D., Stephanopoulos G. Selection and optimization of microbial hosts for biofuels production. Metab. Eng. 2008, 10:295-304.
11. Food and Drug Administration, 2008. Guidance for Industry: Safety Testing of Drug Metabolites. United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
12. Gebhardt R., Hengstler J.G., Muller D., Glockner R., Buenning P., Laube B., Schmelzer E., Ullrich M., Utesch D., Hewitt N., Ringel M., Hilz B.R., Bader A., Langsch A., Koose T., Burger H.J., Maas J., Oesch F. New hepatocyte in vitro systems for drug metabolism: metabolic capacity and recommendations for application in basic research and drug development. Standard Operation Procedures 2003, 35:145-213.
13. Gillam E.M.J., Baba T., Kim B.-R., Ohmori S., Guengerich F.P. Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys. 1993, 305:123-131.
14. Gillam E.M.J., Guo Z., Ueng Y.-F., Yamazaki H., Cock I., Reilly P.E.B., Hooper W.D., Guengerich F.P. Expression of cytochrome P450 3A5 in Escherichia coli: Effects of 5' modifications, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch. Biochem. Biophys. 1995, 317:374-384.
15. Gillam E.M.J., Ueng Y.-F., Wunsch R.M., Shimada T., Kamataki T., Guengerich F.P. Expression of cytochrome P450 3A7 in Escherichia coli: effects of 5' modification and catalytic characterization of recombinant enzyme expressed in bicistronic format with NADPH-cytochrome P450 reductase. Arch. Biochem. Biophys. 1997, 346:81-90.
16. Gotoh O. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analysis of amino acid and coding nucleotide sequences. J. Biol. Chem. 1992, 267:83-90.
17. Guengerich F.P. Human cytochrome P450 enzymes. Cytochrome P450 1995, 473-535. Plenum Press, New York. P.R. Ortiz de Montellano (Ed.).
18. Guengerich F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem. Res. Toxicol. 2001, 14:611-650.
19. Hogg J.A. Steroids, the steroid community, and Upjohn in perspective: a profile of innovation. Steroids 1992, 57.
20. Huang W., Johnston W.A., Hayes M.A., De Voss J.J., Gillam E.M.J. A shuffled CYP2C library with a high degree of structural integrity and functional versatility. Arch. Biochem. Biophys. 2007, 467:193-205.
21. Isin E.M., Guengerich F.P. Complex reactions catalyzed by cytochrome P450 enzymes. Biochim. Biophys. Acta 2007, 1770:314-329.
22. Jezequel S.G. Microbial models of mammalian metabolism: uses and misuses (clarification of some misconceptions). J. Mol. Catal. B - Enzymatic 1998, 5:371-377.
23. Joern J.M. DNA shuffling. Methods Mol. Biol. 2003, 85-89. Humana Press Inc., Totowa, N.J. F.H. Arnold, G. Georgiou (Eds.).
24. Joern J.M., Meinhold P., Arnold F.H. Analysis of shuffled gene libraries. J. Mol. Biol. 2002, 316:643-656.
25. Johnston W.A., Huang W., Hayes M.A., De Voss J.J., Gillam E.M.J. A shuffled CYP1A library shows both structural integrity and functional diversity. Drug Metab. Dispos. 2007, 35:2177-2185.
26. Johnston W.A., Huang W., Hayes M.A., De Voss J.J., Gillam E.M.J. Quantitative whole cell cytochrome P450 measurement suitable for high throughput application. J. Biomol. Screen. 2008, 13:135-141.
27. Khan K.K., He Y.Q., Domanski T.L., Halpert J.R. Midazolam oxidation by cytochrome P450 3A4 and active-site mutants: an evaluation of multiple binding sites and of the metabolic pathway that leads to enzyme inactivation. Mol. Pharmacol. 2002, 61:495-506.
28. Kim D.H., Ahn T., Jung H.C., Pan J.G., Yun C.H. Generation of the human metabolite piceatannol from the anticancer-preventive agent resveratrol by bacterial cytochrome P450 BM3. Drug Metab. Dispos. 2009, 37:932-936.
29. Krauser J.A., Voehler M., Tseng L.-H., Schefer A.B., Godejohann M., Guengerich F.P. Testosterone 1Β-hydroxylation by human cytochrome P450 3A4. Eur. J. Biochem. 2004, 271:3962-3969.
30. Landwehr M., Carbone M., Otey C.R., Li Y., Arnold F.H. Diversification of catalytic function in a synthetic family of chimeric cytochrome P450s. Chem. Biol. 2007, 14:237-238.
31. Landwehr M., Hochrein L., Otey C.R., Kasrayan A., Bäckvall J.-E., Arnold F.H. Enantioselective α-hydroxylation of 2-arylacetic acid derivatives and buspirone catalyzed by engineered cytochrome P450 BM-3. J. Am. Chem. Soc. 2006, 128:6058-6059.
32. Li W., Josephs J.L., Skiles G.L., Humphreys W.G. Metabolite generation via microbial biotransformations with Actinomycetes: rapid screening for active strains and biosynthesis of important human metabolites of two development-stage compounds, 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non7-yl-methyl]-3-thiophenecarboxylic acid (BMS-587101) and Dasatinib. Drug Metab. Dispos. 2008, 36:721-730.
33. Li Y.G., Drummond D.A., Sawayama A.M., Snow C.D., Bloom J.D., Arnold F.H. A diverse family of thermostable cytochrome P450s created by recombination of stabilizing fragments. Nat. Biotech. 2007, 25:1051-1056.
34. Manzoni M., Rollini M. Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl. Microbiol. Biotech. 2002, 58:555-564.
35. Nicoll-Griffith D.A., Seto C., Aubin Y., Levesque J.F., Chauret N., Day S., Silva J.M., Trimble L.A., Truchon J.F., Berthelette C., Lachance N., Wang Z.Y., Sturino C., Braun M., Zamboni R., Young R.N. In vitro biotransformations of the prostaglandin D-2 (DP) antagonist MK-0524 and synthesis of metabolites. Bioorg. Medicinal Chem. Lett. 2007, 17:301-304.
36. Olano C., Lombo F., Mendez C., Salas J.A. Improving production of bioactive secondary metabolites in actinomycetes by metabolic engineering. Metab. Eng. 2008, 10:281-292.
37. Omura T., Sato R. A new cytochrome in liver microsomes. J. Biol. Chem. 1962, 237:1375-1376.
38. Otey C.R., Bandara G., Lalonde J., Takahashi K., Arnold F.H. Preparation of human metabolites of propranolol using laboratory-evolved bacterial cytochromes P450. Biotechnol. Bioeng. 2006, 93:494-499.
39. Otey C.R., Landwehr M., Endelman J.B., Hiraga K., Bloom J.D., Arnold F.H. Structure-guided recombination creates an artificial family of cytochromes P450. PLoS Biol. 2006, 4:e112.
40. Parikh A., Gillam E.M.J., Guengerich F.P. Drug metabolism by Escherichia coli expressing human cytochromes P450. Nat. Biotech. 1997, 15:784-788.
41. Peterson D.H. Microbial transformation of steroids. Introduction of oxygen at carbon-11 of progesterone. J. Am. Chem. Soc. 1952, 74:5933-5936.
42. Petřek M., Otyepka M., Banás P., Kosinová P., Koca J., Damborsky J. CAVER: a new tool to explore routes from protein clefts, pockets and cavities. BMC Bioinformatics 2006, 7:316.
43. Petzoldt K., Annen K., Laurent H., Wiechert R. Process for the Preparation of 11-Beta-Hydroxy Steroids 1982, Schering Aktiengesellschaft, Berlin, Germany.
44. Rushmore T.H., Reider P.J., Slaughter D., Assang C., Shou M. Bioreactor systems in drug metabolism: synthesis of cytochrome P450-generated metabolites. Metab. Eng. 2000, 2:115-125.
45. Stutzman-Engwall, K., Conlon, S., Fedechko, R. McArthur, H., Pekrun, K., Chen, Y., Jenne, S., La, C., Trinh, N., Kim, S., Zhang, Y.-X., Fox, R. Gustafsson, C., Krebber, A., 2005. Semi-synthetic DNA shuffling of aveC leads to improved industrial scale production of doramectin by Streptomyces avermitilis. Metab. Eng. 7, 27-37.
46. Urlacher V.B., Eiben S. Cytochrome P450 monooxygenases: perspectives for synthetic application. Trends Biotech. 2006, 24:324-330.
47. Vail R.B., Homann M.J., Hanna I., Zaks A. Preparative synthesis of drug metabolites using human cytochrome P450s 3A4, 2C9 and 1A2 with NADPH-P450 reductase expressed in Escherichia coli. J. Indust. Microbiol. Biotech. 2005, 32:67-74.
48. van Vugt-Lussenburg B.M.A., Damsten M.C., Maasdijk D.M., Vermeulen N.P.E., Commandeur J.N.M. Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450 BM3. Biochem. Biophys. Res. Commun. 2006, 346:810-818.
49. van Vugt-Lussenburg B.M.A., Damsten M.C., Maasdijk D.M., Vermeulen N.P.E., Commandeur J.N.M. Heterotropic and homotropic cooperativity by a drug-metabolising mutant of cytochrome P450BM3. Biochem. Biophys. Res. Commun. 2006, 346:810-818.
50. van Vugt-Lussenburg B.M.A., Stjernschantz E., Lastdrager J., Oostenbrink C., Vermeulen N.P.E., Commandeur J.N.M. Identification of critical residues in novel drug metabolizing mutants of cytochrome P450 BM3 using random mutagenesis. J. Med. Chem. 2007, 50:455-461.
51. Waxman D.J. Interactions of hepatic cytochromes P-450 with steroid hormones: regioselectivity and stereospecificity of steroid metabolism and hormonal regulation of rat P-450 enzyme expression. Biochem. Pharmacol. 1988, 37:71-84.
52. Waxman D.J., Attisano C., Guengerich F.P., Lapenson D.P. Cytochrome P-450 steroid hormone metabolism catalyzed by human liver microsomes. Arch. Biochem. Biophys. 1988, 263:424-436.
53. Winters D.K., Cederbaum A.I. Expression of a catalytically active human cytochrome P-450 2E1 in Escherichia coli. Biochim. Biophys. Acta 1992, 1156:43-49.
54. Xue L., Zgoda V.G., Arison B., Correia M.A. Structure-function relationships of rat liver CYP3A9 to its human liver orthologs: site-directed active site mutagenesis to a progesterone dihydroxylase. Arch. Biochem. Biophys. 2003, 409:113-126.
55. Yun C.H., Kim K.H., Kim D.H., Jung H.C., Pan J.G. The bacterial P450BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotech. 2007, 25:289-298.
56. Zhang D.L., Zhang H.Y., Aranibar N., Hanson R., Huang Y., Cheng P.T., Wu S., Bonacorsi S., Zhu M.S., Swaminathan A., Humphreys W.G. Structural elucidation of human oxidative metabolites of muraglitazar: use of microbial bioreactors in the biosynthesis of metabolite standards. Drug Metab. Dispos. 2006, 34:267-280.
57. Zhao H.M., Arnold F.H. Optimization of DNA shuffling for high fidelity recombination. Nucl. Acids Res. 1997, 25:1307-1308.